New drug BI 706321 tested for safety in healthy volunteers
NCT ID NCT03971695
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This early-stage trial tested the safety and how the body handles a single dose of the experimental drug BI 706321 in 73 healthy men. The study had two parts: one to check safety and drug levels after increasing doses, and another to compare different pill forms and the effect of food. Since this is a Phase 1 trial in healthy people, there is no direct treatment benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Humanpharmakologisches Zentrum Biberach
Biberach, 88397, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 706321
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.